drugset / Trial / NCT01314781

Therapy of the Overactive Bladder Syndrome

NCT01314781

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of the present study is to investigate in patients with overactive bladder syndrome (OABS) whether a combination treatment of solifenacin with pelvic floor muscle training and whole body vibration training achieves a better treatment outcome than a treatment with solifenacin alone.

Timeline

Start
2012-01
Primary completion
2014-01
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Solifenacin Small molecule 5 mg

Indications